These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36765036)

  • 1. Human epidermal growth factor receptor 3 serves as a novel therapeutic target for acral melanoma.
    Tanaka Y; Ito T; Kaku-Ito Y; Tanegashima K; Tsuji G; Kido-Nakahara M; Oda Y; Nakahara T
    Cell Death Discov; 2023 Feb; 9(1):54. PubMed ID: 36765036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER3 is a determinant for poor prognosis in melanoma.
    Reschke M; Mihic-Probst D; van der Horst EH; Knyazev P; Wild PJ; Hutterer M; Meyer S; Dummer R; Moch H; Ullrich A
    Clin Cancer Res; 2008 Aug; 14(16):5188-97. PubMed ID: 18698037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toward the prognostic significance and therapeutic potential of HER3 receptor tyrosine kinase in human colon cancer.
    Beji A; Horst D; Engel J; Kirchner T; Ullrich A
    Clin Cancer Res; 2012 Feb; 18(4):956-68. PubMed ID: 22142822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding the biology of HER3 receptor as a therapeutic target in human cancer.
    Lyu H; Han A; Polsdofer E; Liu S; Liu B
    Acta Pharm Sin B; 2018 Jul; 8(4):503-510. PubMed ID: 30109175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High G2 and S-phase expressed 1 expression promotes acral melanoma progression and correlates with poor clinical prognosis.
    Xu T; Ma M; Chi Z; Si L; Sheng X; Cui C; Dai J; Yu S; Yan J; Yu H; Wu X; Tang H; Yu J; Kong Y; Guo J
    Cancer Sci; 2018 Jun; 109(6):1787-1798. PubMed ID: 29660787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
    Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
    Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER3 expression in cutaneous tumors.
    Wimmer E; Kraehn-Senftleben G; Issing WJ
    Anticancer Res; 2008; 28(2A):973-9. PubMed ID: 18507044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.
    Lyne JC; Melhem MF; Finley GG; Wen D; Liu N; Deng DH; Salup R
    Cancer J Sci Am; 1997; 3(1):21-30. PubMed ID: 9072304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
    Xia W; Petricoin EF; Zhao S; Liu L; Osada T; Cheng Q; Wulfkuhle JD; Gwin WR; Yang X; Gallagher RI; Bacus S; Lyerly HK; Spector NL
    Breast Cancer Res; 2013; 15(5):R85. PubMed ID: 24044505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear HER3 is associated with favorable overall survival in uveal melanoma.
    Trocmé E; Mougiakakos D; Johansson CC; All-Eriksson C; Economou MA; Larsson O; Seregard S; Kiessling R; Lin Y
    Int J Cancer; 2012 Mar; 130(5):1120-7. PubMed ID: 21484789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
    Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
    Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. STAT3 induces G9a to exacerbate HER3 expression for the survival of epidermal growth factor receptor-tyrosine kinase inhibitors in lung cancers.
    Chang YF; Lim KH; Chiang YW; Sie ZL; Chang J; Ho AS; Cheng CC
    BMC Cancer; 2019 Oct; 19(1):959. PubMed ID: 31619200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy.
    Torka R; Pénzes K; Gusenbauer S; Baumann C; Szabadkai I; Őrfi L; Kéri G; Ullrich A
    Neoplasia; 2014 Apr; 16(4):301-18. PubMed ID: 24862757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers.
    Osada T; Hartman ZC; Wei J; Lei G; Hobeika AC; Gwin WR; Diniz MA; Spector N; Clay TM; Chen W; Morse MA; Lyerly HK
    Breast Cancer Res; 2018 Aug; 20(1):90. PubMed ID: 30092835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells.
    Trono P; Di Modugno F; Circo R; Spada S; Di Benedetto A; Melchionna R; Palermo B; Matteoni S; Soddu S; Mottolese M; De Maria R; Nisticò P
    Oncogene; 2016 Feb; 35(7):887-96. PubMed ID: 25961924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma.
    Qian G; Jiang N; Wang D; Newman S; Kim S; Chen Z; Garcia G; MacBeath G; Shin DM; Khuri FR; Chen ZG; Saba NF
    Cancer; 2015 Oct; 121(20):3600-11. PubMed ID: 26195293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of HER3 activation and tumor growth with a human antibody binding to a conserved epitope formed by domain III and IV.
    Schmitt LC; Rau A; Seifert O; Honer J; Hutt M; Schmid S; Zantow J; Hust M; Dübel S; Olayioye MA; Kontermann RE
    MAbs; 2017 Jul; 9(5):831-843. PubMed ID: 28421882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SATB1-Mediated Upregulation of the Oncogenic Receptor Tyrosine Kinase HER3 Antagonizes MET Inhibition in Gastric Cancer Cells.
    Jenke R; Holzhäuser-Rein M; Mueller-Wilke S; Lordick F; Aigner A; Büch T
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The heregulin/human epidermal growth factor receptor as a new growth factor system in melanoma with multiple ways of deregulation.
    Stove C; Stove V; Derycke L; Van Marck V; Mareel M; Bracke M
    J Invest Dermatol; 2003 Oct; 121(4):802-12. PubMed ID: 14632199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization.
    Hashimoto Y; Koyama K; Kamai Y; Hirotani K; Ogitani Y; Zembutsu A; Abe M; Kaneda Y; Maeda N; Shiose Y; Iguchi T; Ishizaka T; Karibe T; Hayakawa I; Morita K; Nakada T; Nomura T; Wakita K; Kagari T; Abe Y; Murakami M; Ueno S; Agatsuma T
    Clin Cancer Res; 2019 Dec; 25(23):7151-7161. PubMed ID: 31471314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.